C4 Therapeutics, Inc.
$2.99
▲
4.44%
2026-04-21 05:55:01
www.c4therapeutics.com
NMS: CCCC
Explore C4 Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$284.93 M
Current Price
$2.99
52W High / Low
$3.82 / $1.09
Stock P/E
—
Book Value
$2.65
Dividend Yield
—
ROCE
-32.05%
ROE
-44.44%
Face Value
—
EPS
$-1.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
104
Beta
2.86
Debt / Equity
23.38
Current Ratio
7.81
Quick Ratio
7.81
Forward P/E
-2.07
Price / Sales
6.88
Enterprise Value
$58.81 M
EV / EBITDA
-0.57
EV / Revenue
1.64
Rating
None
Target Price
$11.57
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Palvella Therapeutics, Inc. | $129.33 | — | $1.85 B | — | -80.06% | -92.1% | $151.18 / $20.2 | $2.26 |
| 2. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 3. | Karyopharm Therapeutics Inc. | $8.94 | — | $193.06 M | — | -554.58% | 81.86% | $10.99 / $3.65 | $-16 |
| 4. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 5. | Omeros Corporation | $13.47 | — | $997.87 M | — | -49.6% | 2.21% | $17.65 / $2.95 | $-1.69 |
| 6. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 7. | Plus Therapeutics, Inc. | $7.3 | — | $50.09 M | — | -381.4% | 903.94% | $30.5 / $2.9 | $0.72 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 11.02 M | 11.23 M | 6.46 M | 7.24 M | 5.18 M | — |
| Operating Profit | -23.14 M | -23.68 M | -28.5 M | -29.16 M | -37.71 M | — |
| Net Profit | -20.49 M | -32.17 M | -26.02 M | -26.32 M | -34.57 M | — |
| EPS in Rs | -0.21 | -0.33 | -0.27 | -0.27 | -0.35 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 35.95 M | 35.58 M | 20.76 M | 31.1 M |
| Operating Profit | -104.49 M | -117.18 M | -139.03 M | -129.53 M |
| Net Profit | -104.99 M | -105.32 M | -132.49 M | -128.18 M |
| EPS in Rs | -1.08 | -1.08 | -1.36 | -1.31 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 359.07 M | 349.6 M | 376.45 M | 430.84 M |
| Total Liabilities | 102.49 M | 133.62 M | 130.34 M | 141.61 M |
| Equity | 256.59 M | 215.99 M | 246.11 M | 289.23 M |
| Current Assets | 258.11 M | 257.77 M | 271.19 M | 287.56 M |
| Current Liabilities | 33.03 M | 45.18 M | 42.77 M | 44.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -98.69 M | -65.16 M | -106.84 M | -105.94 M |
| Investing CF | -8.6 M | -51.27 M | 158.35 M | 58.42 M |
| Financing CF | 126.4 M | 45.34 M | 45.49 M | 1.15 M |
| Free CF | -99.3 M | -65.34 M | -108.55 M | -111.44 M |
| Capex | -0.61 M | -0.18 M | -1.71 M | -5.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 71.44% | -33.25% | — | — |
| Earnings Growth % | 20.51% | -3.37% | — | — |
| Profit Margin % | -295.96% | -638.34% | -412.19% | — |
| Operating Margin % | -329.3% | -669.84% | -416.56% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -324.19% | -616.5% | -399.68% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.